Skip to main content

Table 3 Details of recurrent patients and their local-regional failures

From: Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma

     Dose–volume histograms statistics to recurrence volume  
No. Stage Site of relapse Location of the recurrence volume Vrecur (cc) Dmean (Gy) Dmin (Gy) Dmax (Gy) V95%(%) Type of relapsea
1 T4N3b Local CTV 13.9 69.9 48.5 75.2 97.9 In-field
   Regional CTV 2.7 68.9 64.6 71.3 100 In-field
2 T4N1 Local Marginal to CTV 10.5 70 51.5 77 94.3 marginal
3 T4N0 Local CTV 32.9 70.9 37.6 75.4 97.7 In-field
4 T3N3b Local Marginal to CTV 13.9 62.1 11.8 74.1 74.7 marginal
   Regional CTV 3.6 67.5 63.9 71.9 100 In-field
5 T2N1 Local CTV 15.1 67.6 60 71.2 100 In-field
6 T1N0 Local CTV 10.2 65.1 53.3 71.7 100 In-field
7 T3N3b Local CTV 2.2 70 63 76.8 100 In-field
   Regional Outside CTV 8.4 14.2 11.2 37.7 - outside
8 T3N1 Local GTV 10.6 73.5 69.1 76.3 100 In-field
   Regional CTV 5.5 69.6 65.9 73.6 100 In-field
9 T4N0 Local GTV 9.3 72 61.8 74 99.2 In-field
10 T3N2 Local CTV 15.2 71.9 63.3 77.3 100 In-field
11 T4N1 Local CTV 8 72.1 66 73.8 100 In-field
12 T4N3b Regional - - - - - - -
13 T3N2 Regional CTV 20.6 67.8 51.2 72.6 99.6 In-field
14 T2N1 Regional 1 Outside CTV 3.6 45.3 34.6 56.7 - outside
   Regional 2 Marginal to CTV 12.6 53.4 20.6 66.7 32.5 marginal
   Regional 3 Outside CTV 2.7 54.2 46.6 61.4 19.1 outside
15 T3N2 Regional - - - - - - -
16 T3N3b Regional CTV 4.2 66.5 61.3 69.3 100 In-field
17 T1N2 Regional GTV 2.2 70.1 67.9 72.4 100 In-field
18 T3N3b Regional 1 - - - - - - -
   Regional 2 CTV 22.2 65.6 51.4 73 98.8 In-field
  1. CTV clinical target volume, GTV gross tumor volume; V95%=% of volume of failure receiving at least 95% of prescribed total dose, Vrecur the recurrent tumor volume.
  2. aIn-field refers to 95% of the recurrence volume receiving more than 95% of the prescribed dose. Marginal refers to 20–95% of the recurrence volume receiving 95% of the prescribed dose. Outside refers to less than 20% of the the recurrence volume receiving 95% of the prescribed dose.